Quadrant Biosciences Enters into Licensing Agreements for Commercialization of Novel Epigenetic Biomarkers to Detect Autism, Parkinson's, and Concussion

Quadrant Biosciences announced today the execution of three licensing agreements with SUNY Upstate Medical University and Penn State University for the global commercialization of epigenetic biomarkers for three important health issues facing society today: autism spectrum disorder ("ASD"), Parkinson's disease and mTBI (concussion).